---
title: "Organon & Co. 2026: Revenue $1.56B, EPS $0.4— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294511535.md"
description: "Organon & Co. reported Q2 2026 results with revenue of $1.56B and diluted EPS of $0.4, down from prior-year figures. The company is proceeding with its acquisition by Sun Pharma at $14.00 per share, expected to close in early 2027. Worldwide sales declined roughly 2% in Q2, though foreign exchange provided a positive impact. Brand performance was mixed, with growth in Hadlima and Emgality offset by declines in Nexplanon and Singulair. Organon also recognized $31M in restructuring charges while executing supply-chain separations."
datetime: "2026-07-31T12:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294511535.md)
  - [en](https://longbridge.com/en/news/294511535.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294511535.md)
generator: "portal-rs"
---

# Organon & Co. 2026: Revenue $1.56B, EPS $0.4— 10-Q Summary

Organon & Co. reported results for the 2026 quarter, with revenue of $1.56B, net income of $108M and diluted EPS of $0.4, against $1.59B, $145M and $0.56 in the prior-year quarter, respectively.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$1.56B

$1.59B

(2.3%)

Net income²

$108M

$145M

(25.5%)

Diluted EPS³

$0.4

$0.56

(28.6%)

*¹ Reported as “Revenues”. ² Reported as “Net income”. ³ Reported as “Diluted earnings per share”.*

**Business Highlights**

-   Definitive agreement reached to be acquired by Sun Pharma for $14.00 per share; stockholder approval received and closing expected in early 2027.
-   Worldwide sales declined roughly 2% in Q2 and 3% year-to-date 2026; foreign exchange had a positive impact (about 3% in Q2 and 4% YTD).
-   Brand performance mixed: strong growth for Hadlima, Emgality and Zetia/Vytorin; notable declines in Nexplanon, Singulair, Ontruzant and Jada.
-   Commercial changes included divestiture of the Jada System, expanded Samsung biosimilars commercialization rights, and $30M in fixed commitments paid.
-   Company is executing restructuring and supply-chain separations, recognizing $31M of restructuring charges year-to-date and advancing manufacturing and network optimization.

Original SEC Filing: Organon & Co. \[ OGN \] - 10-Q - Jul. 31, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [OGN.US](https://longbridge.com/en/quote/OGN.US.md)

## Related News & Research

- [Sun Pharma signs US drug pricing deal, secures tariff relief for 2 years](https://longbridge.com/en/news/297591064.md)
- [Organon agrees to supplement proxy after NJ suit; provides financial projections and synergy estimate](https://longbridge.com/en/news/293070564.md)
- [SPAYZ.io brings Africa’s payment growth story to Forex Expo Dubai 2026](https://longbridge.com/en/news/298013003.md)
- [Morgan Stanley lifts Mercedes-Benz voting rights stake to 5.24% from 4.99%](https://longbridge.com/en/news/298006718.md)
- [Royal Caribbean Group announces dividend of R$ 0.27 per unit, payable Oct. 15](https://longbridge.com/en/news/297928955.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**